Altimmune ALT 深 沪
等待开盘 07-30 09:30:00 美东时间
3.83
-0.200
-4.96%
华盛通- 最 高4.0263
- 今 开4.01
- 成交量 264.76万股
- 最 低 3.7403
- 昨 收 4.03
- 总市值 3.11亿
- 52周最高 11.16
- 市盈率 静 --
- 换手率 3.26%
- 52周最低 2.90
- 委 比 -2.76%
- 总股本 8110.70万
- 历史最高 237.30
- 量 比 1.71
- 振 幅 7.10%
- 历史最低 1.51
- 每 手 1
- 风险率 2.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stanley Black & Decker Reports 2Q 2025 Results
DEWALT Delivered Topline Growth Due to Relatively Resilient Professional Demand Continued Cost Discipline and Price Measures Partially Mitigated External Pressures and Helped Protect Profit...
07-29 18:00
146%！波士顿科学净利暴涨
作者 | 秦酒 波士顿科学再次交出了一份令市场瞩目的成绩单。 01 2025年Q2净利翻倍 波士顿上调全年盈利指引 7月23日，波士顿科学公布2025财年...
07-24 19:23
Viking Therapeutics EPS miss sends shares down 7%
Viking Therapeutics (NASDAQ:VKTX) is down ~7% in after-hours trading Wednesday after its Q2 bottom line results missed the mark. The company did not report any revenue. The biotech saw its net loss wi...
07-24 05:51
Alturas Minerals Shifts Focus After Lease Lapse and Plans Debt Conversion
Alturas Minerals ( ($TSE:ALT) ) has shared an announcement. Alturas Minerals ha...
07-23 01:38
Madrigal gains after Rezdiffra patent win
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded higher in the premarket on Wednesday after the company announced a patent win related to its lead asset, Rezdiffra, approved by the FDA in 2024 for a live...
07-16 20:54
猎杀多头 比特币暴跌5000点 这只是暴跌的开始？
昨晚信息面上因特朗普针对俄罗斯有重大声明形成利空，btc自123300回落回踩到当前118250,共有 141,253 人被爆仓 ，爆仓总金额为 $8.10 亿...
07-15 12:31
Maria Ford Appointed to Forbes Business Development Council
Maria Ford, President of U.S. Commercial & Industrial Sales, joins exclusive Council to share insights on matters impacting the construction industry and empowering the next generation of tr...
07-14 20:00
Altimmune Enrols First Patient In RESTORE Phase 2 Trial Evaluating Efficacy And Safety Of Pemvidutide In Subjects With Alcohol-Associated Liver Disease
Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in
07-09 19:31
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc. has enrolled the first patient in the RESTORE Phase 2 trial evaluating pemvidutide for Alcohol-Associated Liver Disease (ALD). Pemvidutide, a GLP-1/glucagon dual receptor agonist, aims to treat ALD, obesity, and metabolic disorders. The trial, led by Dr. Rohit Loomba, will enroll ~100 patients across 34 sites, testing 2.4mg pemvidutide versus placebo over 48 weeks. The primary endpoint is liver stiffness reduction at Week 24, with...
07-09 11:30
ALT5 Sigma Appoints David Danziger to Board
ALT5 Sigma Corporation ( ($ALTS) ) just unveiled an update. On June 27, 2025, A...
07-04 04:58
